Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$0.52 USD
0.00 (0.64%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $0.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
GOSS 0.52 0.00(0.64%)
Will GOSS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GOSS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GOSS
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
GOSS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes Gossamer Bio (GOSS) a New Buy Stock
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy
Other News for GOSS
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Buy Rating Reaffirmed for Gossamer Bio on Seralutinib’s Promising Clinical Data and Future Prospects
Wall Street Analysts Are Bullish on Top Healthcare Picks